# InCarda Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/incarda-therapeutics

- Industry: Biotechnology
- Headquarters: Newark, US
- Website: www.incardatherapeutics.com
- Total disclosed funding: $75M
- Latest round: Series C (Oct 6, 2020)
- Investors on record: 6

## About

InCarda Therapeutics is a biopharmaceutical company specializing in innovative inhalation therapies for cardiovascular diseases, particularly targeting paroxysmal atrial fibrillation with its lead product, an inhaled formulation of flecainide.Founded in 2009 and headquartered in Newark, US, InCarda Therapeutics focuses on developing inhalation therapies for cardiovascular conditions. The company was founded by Carlos Schuler and Narsi R. In October 2020, InCarda raised USD 27.99 mn in Series C funding led by Innoviva, Inc., with participation from Deerfield Management, HealthCap, and Morningside Venture Capital. The total amount raised by the company amounts to USD 27.99 mn, with a current valuation of USD 163.82 mn.InCarda Therapeutics develops a unique inhalation therapy for treating acute episodes of paroxysmal atrial fibrillation (PAF). Their lead product is an orally inhaled formulation of flecainide, which directly delivers therapeutic agents to cardiac tissue, ensuring rapid action with minimized systemic exposure. This targeted delivery enhances both efficacy and safety. The company's products are marketed to healthcare providers and institutions in regions with high atrial fibrillation prevalence, including North America and Europe.InCarda Therapeutics generates revenue through direct sales of its inhalation therapy products to healthcare facilities and practitioners. The sales process typically involves business-to-business arrangements, allowing healthcare providers to purchase the medication directly for administering to patients experiencing acute episodes of PAF. Their pricing models are structured to meet the needs of healthcare providers, including bulk purchasing agreements or subscription models, with the inhaled flecainide therapy expected to be a major revenue contributor.InCarda Therapeutics plans to utilize the USD 27.99 mn raised in Series C funding to support the development of new products and expand into new markets. This funding will be allocated towards the launch of their inhalation therapy for PAF, which is currently in the pipeline, and will enhance their product offerings. The company is targeting expansion in North America and Europe, aiming to establish a strong presence in these regions by the end of 2022.

## Funding rounds

- Series C, Oct 6, 2020, $28M — HealthCap, 5Y Capital, Deerfield Management, Innoviva, Inc.
- Series B, Nov 8, 2018, $42M — Sofinnova Partners, HealthCap, 5Y Capital, Asset Management Ventures, Deerfield Management
- Series A, Apr 1, 2015, $5M — 5Y Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A, Series B, Series C
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series B
- HealthCap — Series B, Series C
- Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B, Series C
- Innoviva, Inc. — Series C